67 related articles for article (PubMed ID: 9607567)
21. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
22. 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells.
Johnson KR; Wang L; Miller MC; Willingham MC; Fan W
Clin Cancer Res; 1997 Oct; 3(10):1739-45. PubMed ID: 9815558
[TBL] [Abstract][Full Text] [Related]
23. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
[TBL] [Abstract][Full Text] [Related]
24. Raf-1 kinase activity predicts for paclitaxel resistance in TP53mut, but not TP53wt human ovarian cancer cells.
Britten RA; Perdue S; Eshpeter A; Merriam D
Oncol Rep; 2000; 7(4):821-5. PubMed ID: 10854551
[TBL] [Abstract][Full Text] [Related]
25. Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells.
Chun E; Lee KY
Biochem Biophys Res Commun; 2004 Mar; 315(3):771-9. PubMed ID: 14975768
[TBL] [Abstract][Full Text] [Related]
26. Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis.
Vikhanskaya F; Vignati S; Beccaglia P; Ottoboni C; Russo P; D'Incalci M; Broggini M
Exp Cell Res; 1998 May; 241(1):96-101. PubMed ID: 9633517
[TBL] [Abstract][Full Text] [Related]
27. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
28. Relationship between paclitaxel activity and pathobiology of human solid tumors.
Gan Y; Wientjes MG; Au JL
Clin Cancer Res; 1998 Dec; 4(12):2949-55. PubMed ID: 9865905
[TBL] [Abstract][Full Text] [Related]
29. BAD partly reverses paclitaxel resistance in human ovarian cancer cells.
Strobel T; Tai YT; Korsmeyer S; Cannistra SA
Oncogene; 1998 Nov; 17(19):2419-27. PubMed ID: 9824152
[TBL] [Abstract][Full Text] [Related]
30. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
31. Paclitaxel is preferentially cytotoxic to human cervical tumor cells with low Raf-1 kinase activity: implications for paclitaxel-based chemoradiation regimens.
Britten RA; Perdue S; Opoku J; Craighead P
Radiother Oncol; 1998 Sep; 48(3):329-34. PubMed ID: 9925253
[TBL] [Abstract][Full Text] [Related]
32. Src tyrosine kinase but not activated Ras augments sensitivity to taxanes through apoptosis in human adenocarcinoma cells.
Boudny V; Nakano S
Anticancer Res; 2003; 23(1A):7-12. PubMed ID: 12680188
[TBL] [Abstract][Full Text] [Related]
33. Down-regulation of Raf-1 kinase is associated with paclitaxel resistance in human breast cancer MCF-7/Adr cells.
Lee M; Koh WS; Han SS
Cancer Lett; 2003 Apr; 193(1):57-64. PubMed ID: 12691824
[TBL] [Abstract][Full Text] [Related]
34. The enhancement of Raf-1 kinase activity by knockdown of Spry2 is associated with high sensitivity to paclitaxel in v-Ha-ras-transformed NIH 3T3 fibroblasts.
Ahn JH; Eum KH; Lee M
Mol Cell Biochem; 2009 Dec; 332(1-2):189-97. PubMed ID: 19588231
[TBL] [Abstract][Full Text] [Related]
35. Comparison of strategies targeting Raf-1 mRNA in ovarian cancer.
Mullen P; McPhillips F; Monia BP; Smyth JF; Langdon SP
Int J Cancer; 2006 Mar; 118(6):1565-71. PubMed ID: 16184551
[TBL] [Abstract][Full Text] [Related]
36. Characterization of paclitaxel (Taxol) sensitivity in human glioma- and medulloblastoma-derived cell lines.
Tseng SH; Bobola MS; Berger MS; Silber JR
Neuro Oncol; 1999 Apr; 1(2):101-8. PubMed ID: 11550305
[TBL] [Abstract][Full Text] [Related]
37. Cytotoxicity and apoptosis of ovarian and breast cancer cell lines induced by OVS1 monoclonal antibody and paclitaxel.
Moongkarndi P; Kaslungka S; Kosem N; Junnu S; Jongsomboonkusol S; Theptaranon Y; Neungton N
Asian Pac J Allergy Immunol; 2003 Mar; 21(1):31-41. PubMed ID: 12931749
[TBL] [Abstract][Full Text] [Related]
38. Insulin can modulate MCF-7 cell response to paclitaxel.
Miglietta A; Panno ML; Bozzo F; Gabriel L; Bocca C
Cancer Lett; 2004 Jun; 209(2):139-45. PubMed ID: 15159015
[TBL] [Abstract][Full Text] [Related]
39. Paclitaxel restores radiation-induced apoptosis in a bcl-2-expressing, radiation-resistant lymphoma cell line.
Nguyen LN; Munshi A; Hobbs ML; Story MD; Meyn RD
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1127-32. PubMed ID: 11240255
[TBL] [Abstract][Full Text] [Related]
40. Cytostatic and apoptotic effects of paclitaxel in human breast tumors.
Gan Y; Wientjes MG; Lu J; Au JL
Cancer Chemother Pharmacol; 1998; 42(3):177-82. PubMed ID: 9685052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
